<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":9274,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Walker v. Medtronic, Inc., 670 F.3d 569 (4th Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/2ea6e549928ae1522970500c9cdba52f'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/2ea6e549928ae1522970500c9cdba52f'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='Walker v. Medtronic, Inc., 670 F.3d 569 (4th Cir. 2012), Court Opinion'>
Walker v. Medtronic, Inc., 670 F.3d 569 (4th Cir. 2012), Court Opinion
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Walker v. Medtronic, Inc., 670 F.3d 569 (4th Cir. 2012), Court Opinion</div>
<div class='docId'>X1H14RI003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Walker v. Medtronic, Inc.</div>
<div class='displayCitation'>2012 BL 16026</div>
<div class='displayCitation'>670 F.3d 569</div>
<div class='displayCitation'>bna a0d0p4a6f2</div>
<div class='displayCitation'>wkf4case:25708985</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1H14RI003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Walker v. Medtronic, Inc., 670 F.3d 569 (4th Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Walker v. Medtronic, Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X1H14RI003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1H14RI003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1H14RI003" /><input id="title" name="title" type="hidden" value="Walker v. Medtronic, Inc., 670 F.3d 569 (4th Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="2ea6e549928ae1522970500c9cdba52f" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1H14RI003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="false" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%32ea%36e%35%34%39%39%32%38ae%31%35%32%32%39%37%30%35%30%30c%39cdba%35%32f%2Fdocument%2FX%31H%31%34RI%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/bcite/X1H14RI003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/bcite/X1H14RI003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/bcite/X1H14RI003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/related_content/X1H14RI003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1684864040963";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">670 F.3d 569</div>
<div class="cite" data-cite-type="DocketNumber">10-2219</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 16026</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Fourth Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
Sherry Ann WALKER, Individually and as Administratrix of the Estate of
Arnold Leroy Walker, Jr., Plaintiff-Appellant, v. MEDTRONIC,
INCORPORATED, a Minnesota corporation, Defendant-Appellee, and Medtronic
USA, Incorporated, a Minnesota corporation, Defendant.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 10-2219.
</center></p>
<p><center>
Argued: November 8, 2011.
</center></p>
<p><center>
Decided: January 25, 2012.
</center></p>
<span CLASS="page_no" data-cite="670 f 3d 570" data-cite-type="PrimaryFederalReporter" data-cite-pageno="570" data-primary-citation="670 F.3d 569">[*570]</span> <div id="para2" printdualcolumn="true"><p>
  Appeal from the United States District Court for the
Southern District of West Virginia, David A. Faber, Senior
District Judge.
<span CLASS="page_no" data-cite="670 f 3d 571" data-cite-type="PrimaryFederalReporter" data-cite-pageno="571" data-primary-citation="670 F.3d 569">[*571]</span> 
</p></div>
<div id="para2" printdualcolumn="true"><p>
  <b>ARGUED:</b> Christopher Brinkley, Masters Law Firm,
LC, Charleston, West Virginia, for Appellant. Andrew E. Tauber,
Mayer Brown, LLP, Washington, D.C., for Appellee. <b>ON</b>
<b>BRIEF:</b> David M. Gossett, Brette L. Steele, Mayer Brown,
LLP, Washington, D.C., for Appellee.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Before DUNCAN, WYNN, and DIAZ, Circuit Judges.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Affirmed by published opinion. Judge DUNCAN wrote the majority
opinion, in which Judge DIAZ joined. Judge WYNN wrote a
dissenting opinion.
</p></div>
<div id="contentOpinion" printdualcolumn="true"><div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                 <b>OPINION</b>
</p></div></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  DUNCAN, Circuit Judge:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellant Sherry Walker appeals from the district court's
holding that her common law tort claims against Medtronic, Inc.
are preempted by the Medical Device Amendments of 1976 ("MDA"),
as interpreted by <i>Riegel v. Medtronic, Inc.</i>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. 312</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=169%20l%20ed%202d%20892&amp;summary=yes#jcite">169 L.Ed.2d 892</a> (2008). Walker argues that,
because the device in question allegedly failed to operate in
accordance with the terms of its premarket approval, her claims
parallel federal requirements and therefore should avoid
preemption. In light of Walker's concession that the device was
designed, manufactured, and distributed in compliance with the
terms of its premarket approval, given by the Food and Drug
Administration ("FDA") as required under the MDA, however, we
are compelled to affirm.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The exclusive provisions of the FDA regulatory process
recognize only one mechanism for the creation of an enforceable
requirement governing the ongoing performance of a medical
device, and that is through the establishment of a formal
performance standard. Walker concedes that no such performance
standard was created here. This concession makes clear that her
common law claims seek to impose requirements above and beyond
those of the FDA, thus bringing them within the
<span CLASS="page_no" data-cite="670 f 3d 572" data-cite-type="PrimaryFederalReporter" data-cite-pageno="572" data-primary-citation="670 F.3d 569">[*572]</span> 
category expressly preempted by the MDA. To hold otherwise
would be to undermine the balance Congress struck when it
enacted the MDA, in which it determined that the benefit to the
many of bringing potentially lifesaving, but risky, medical
devices to the public following the rigorous process of FDA
approval outweighed the cost to the few of preempting common
law claims based on different standards.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   I.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   A.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In 1976, Congress passed the Medical Device Amendments,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PI003?jcsearch=21%20usc%20360c&amp;summary=yes#jcite">21 U.S.C. &sect; 360c</a> et seq., in order to "impose[] a regime of
detailed federal oversight" to govern medical devices.
<i>Riegel</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 316</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. It did so in
response to mounting concern following the highly publicized
controversy surrounding the Dalkon Shield intrauterine device,
which "demonstrated the inability of the common law tort system
to manage the risks associated with dangerous devices."
<i></i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id. at 315</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. As such, Congress
intentionally "swept back some <span CLASS="page_no" data-cite="2012 bl 16026 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[**2]</span> state obligations" in favor of
uniform federal regulation. <i></i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20U.S.%20at%20323&amp;summary=yes#jcite">Id. at 316</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To that end, the MDA includes a provision expressly preempting
state regulation of medical devices. It states in relevant
part:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  [N]o State or political subdivision of a State may
  establish or continue in effect with respect to a
  device intended for human use any requirement &mdash;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (1) which is different from, or in addition to, any
  requirement applicable under this chapter to the
  device, and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (2) which relates to the safety or effectiveness of
  the device or to any other matter included in a
  requirement applicable to the device under this
  chapter.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5Q2003?jcsearch=21%20U.S.C.%20%20360k(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 360k</a>(a).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The MDA also establishes three classes of medical devices,
organized according to the level of oversight required to
ensure their safety. Class I devices are those for which
general controls, such as labeling requirements, "are
sufficient to provide reasonable assurance of [their]
safety and effectiveness." <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PI003?jcsearch=21%20U.S.C.%20%20360c(a)(1)(A)(i)&amp;summary=yes#jcite">21 U.S.C. &sect; 360c</a>(a)(1)(A)(i).
They include such things as "elastic bandages and examination
gloves" and are "subject to the lowest level of oversight."
<i>Riegel</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 316</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. Class II
devices include "such devices as powered wheel-chairs and
surgical drapes," <i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">id</a>.</i>, and are subject to heightened
oversight mechanisms, such as "performance standards [and]
postmarket surveillance," <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PI003?jcsearch=21%20U.S.C.%20%20360c(a)(1)(B)&amp;summary=yes#jcite">21 U.S.C. &sect; 360c</a>(a)(1)(B).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Class III devices require the highest level of federal
oversight. Class III devices are those for which the general
controls regulating Class I devices and the specific controls
that regulate Class II devices are deemed insufficient to
ensure safety and effectiveness, and that are either useful in
"supporting or sustaining human life or for a use which is of
substantial importance in preventing impairment of human
health" or that "present[] a potential unreasonable risk of
illness or injury." <i><cite>Id</cite>.</i> at <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PI003?jcsearch=21%20U.S.C.%20%20360c(a)(1)(C)&amp;summary=yes#jcite">&sect; 360c(a)(1)(C)</a>.
Because of the risks associated with them, Class III devices
are required to go through pre-market approval "to provide
reasonable assurance of [their] safety and effectiveness."
<i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PI003?jcsearch=21%20U.S.C.%20%20360c(a)(1)(C)&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "Premarket approval is a rigorous process." <i>Riegel</i>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 317</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a> (internal quotation marks
omitted). To obtain pre-market approval, a device manufacturer
must submit to the FDA full reports of all investigations
relating to the
<span CLASS="page_no" data-cite="670 f 3d 573" data-cite-type="PrimaryFederalReporter" data-cite-pageno="573" data-primary-citation="670 F.3d 569">[*573]</span> 
device's safety or effectiveness; a "full statement of the
components, ingredients, and properties and of the principle or
principles of operation" of the device; a full description of
the manufacturing methods and the facilities and controls used
for the device's manufacturing; references to any performance
standards applicable to the device; samples of the device and
any component parts; examples of the proposed labeling for the
device; and other information as requested.
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PM003?jcsearch=21%20U.S.C.%20%20360e(c)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 360e</a>(c)(1). This typically requires a "multivolume
application." <i>Riegel</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 317</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA reviews these applications, approving only those it has
determined provide reasonable assurance of a device's safety
and effectiveness. It "spends an average of 1,200 hours
reviewing each application." <i></i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id. at 318</a>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. If the FDA deems it necessary, it may refer an application
to a panel of experts "for study and for submission . . . of a
report and <span CLASS="page_no" data-cite="2012 bl 16026 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[**3]</span> recommendation respecting approval of the
application, together with all underlying data and the reasons
or basis for the recommendation." <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PM003?jcsearch=21%20U.S.C.%20%20360e(c)(3)&amp;summary=yes#jcite">21 U.S.C. &sect; 360e</a>(c)(3).
The FDA's final grant of pre-market approval is based on
"weighing any probable benefit to health from the use of [a]
device against any probable risk of injury or illness from such
use." <i><cite>Id</cite>.</i> at <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PI003?jcsearch=21%20U.S.C.%20%20360c(a)(2)(C)&amp;summary=yes#jcite">&sect; 360c(a)(2)(C)</a>. "It may thus approve
devices that present great risks if they nonetheless offer
great benefits in light of available alternatives."
<i>Riegel</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 318</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA may condition its grant of premarket approval upon
certain requirements. Significantly for our purposes, the FDA
may require that a device meet certain performance standards if
it "determines that a performance standard is necessary to
provide reasonable assurance of the safety and effectiveness of
the device." <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PK003?jcsearch=21%20U.S.C.%20%20360d(a)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 360d</a>(a)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The establishment of a performance standard is a formal process
specifically governed by the MDA. It requires publication of a
notice of proposed rulemaking in the Federal Register setting
forth justification why the performance standard is necessary,
"proposed findings with respect to the risk of illness or
injury that the performance standard is intended to reduce or
eliminate," and invitation for comments from interested
persons.<a HREF="#fn100" name="fnref_fn100">[fn1]</a> <i><cite>Id</cite>.</i> at <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PK003?jcsearch=21%20U.S.C.%20%20360d(b)(1)(B)&amp;summary=yes#jcite">&sect; 360d(b)(1)(B)</a>. Following
the expiration of the comment period and consideration of the
comments submitted therein, the FDA must promulgate a
regulation establishing a formal performance standard and
publish it in the Federal Register. <i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/1?citation=21%20U.S.C.%20360d(b)(1)(B)&amp;summary=yes#jcite">Id</a>.</i> at
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PK003?jcsearch=21%20U.S.C.%20%20360d(b)(3)(A)&amp;summary=yes#jcite">&sect; 360d(b)(3)(A)</a>. When the FDA establishes a performance standard
for a Class III device, it does so as a precursor to the grant
of premarket approval. <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XMJ9N4003?jcsearch=21%20C.F.R.%20%20861.1(b)(3)&amp;summary=yes#jcite">21 C.F.R. &sect; 861.1</a>(b)(3).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Once premarket approval has been granted, "the MDA forbids the
manufacturer to make, without FDA permission, changes in design
specifications, manufacturing process, labeling, or any other
attribute, that would affect safety or effectiveness."
<i>Riegel</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 319</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. To gain FDA
approval of a proposed change, the manufacturer must submit a
supplemental application describing the change in detail and
summarizing the findings supporting the change.
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PM003?jcsearch=21%20U.S.C.%20%20360e(d)(6)(A)(i)&amp;summary=yes#jcite">21 U.S.C. &sect; 360e</a>(d)(6)(A)(i). A premarket approval application supplement
is "evaluated under largely the same criteria as an
<span CLASS="page_no" data-cite="670 f 3d 574" data-cite-type="PrimaryFederalReporter" data-cite-pageno="574" data-primary-citation="670 F.3d 569">[*574]</span> 
initial application." <i>Riegel</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 319</a>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA continues to oversee Class III devices after the grant
of pre-market approval. Manufacturers must report to the FDA
when an approved device "may have caused or contributed to a
death or serious injury" or malfunctioned in a way that would
make it likely to do so in the future.
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PU003?jcsearch=21%20U.S.C.%20%20360i(a)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 360i</a>(a)(1). They also must periodically inform the FDA about
data from clinical studies or scientific literature related to
the device. <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XMJ9H0003?jcsearch=21%20C.F.R.%20%20814.84(b)&amp;summary=yes#jcite">21 C.F.R. &sect; 814.84</a>(b). "The FDA has the power
to withdraw premarket approval based on newly reported data or
existing information and must withdraw approval if it
determines that a device is unsafe or ineffective under the
conditions in its labeling." <i>Riegel</i>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 319-20</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   B.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The device at issue here is a Model 8627-18 SynchroMed EL
Programmable Pump (the "SynchroMed pump"), which was designed,
manufactured, and distributed by Medtronic. The SynchroMed pump
is <span CLASS="page_no" data-cite="2012 bl 16026 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[**4]</span> a component part of the SynchroMed Infusion System, a method
of delivering medication designed for patients who require
chronic infusions of drugs. Specifically, the system delivers
medication directly into the space surrounding the spinal cord.
It accomplishes this through implantation of the SynchroMed
pump in the patient's abdominal area and implantation of a
catheter in the patient's interspinal space. The SynchroMed
pump is connected to the catheter and programmed to deliver a
controlled amount of medication at the dosage and frequency
prescribed by a physician.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The SynchroMed pump is undisputedly a Class III device with
respect to which the FDA granted premarket approval. The FDA
originally approved Medtronic's application for the SynchroMed
pump in 1988; it subsequently granted premarket approval to
application supplements in 1994 and 1999. It is further
undisputed that neither the FDA's initial grant of premarket
approval nor its later approvals of supplemental applications
were subject to any requirement that the SynchroMed pump comply
with a formal performance standard pursuant to <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PK003?jcsearch=21%20U.S.C.%20%20360d&amp;summary=yes#jcite">&sect; 360d</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In relevant part, the FDA's March 18, 1999 approval letter
stated that the SynchroMed pump had been modified by
"extend[ing] down" the flow range "to 0.048 ml/day from 0.098
ml/day, while maintaining the delivery accuracy of &plusmn;
15%." J.A. 93. It also noted the "[c]hange to the labeling for
. . . new delivery accuracy (0.048 ml &plusmn; 15%)."
<i><cite>Id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Technical Manual for the SynchroMed pump &mdash; which was
approved by the FDA during the premarket approval process and
is distributed along with the device &mdash; likewise specified
that "[t]he flow accuracy of the SynchroMed EL pump, measured
at the catheter tip, is within &plusmn; 15 percent of the
programmed flow rate." J.A. 153. It qualified this statement,
however: "[T]he accuracy of the SynchroMed EL Infusion System
depends on how closely procedures are followed. Noncompliance
with implant and refill procedures, as well as other human
factors, may cause the observed accuracy of the system to vary
by &plusmn; 25 percent." <i><cite>Id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Technical Manual contained other warnings about the risks
associated with use of the SynchroMed pump. Of significance
here, it stated:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Improper use of implanted, programmable infusion pumps
  could result in drug overdose. Users must comply with
  product instructions for initial pump preparation,
  programming, implantation,
<span CLASS="page_no" data-cite="670 f 3d 575" data-cite-type="PrimaryFederalReporter" data-cite-pageno="575" data-primary-citation="670 F.3d 569">[*575]</span> 
  initial filling,
  refilling, and injecting into the side catheter access
  port (if present) of the pump. Technical errors may
  result in a return of underlying symptoms, drug
  withdrawal symptoms, or a clinically significant or
  fatal drug overdose.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A. 107. It further noted that possible pump complications
included a "[c]hange in flow performance characteristics, due
to component failure or changes over time, which may result in
. . . overinfusion of the drug [or] drug overdose." J.A. 109.
Finally, it included the following special notice:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The pump and catheter are implanted in the extremely
  hostile environment of the human body. This
  environment places severe demands on their design <span CLASS="page_no" data-cite="2012 bl 16026 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[**5]</span> and
  function. . . . Reasons for failure of the pump or
  catheter include, but are not limited to: body
  rejection phenomena; change in performance
  characteristics due to component changes or failures;
  unusual physiological variations in patients; medical
  complications; complete or partial catheter occlusion;
  catheter dislodgement; catheter leakage; catheter
  breakage; migration; or erosion of the pump. In
  addition, despite the exercise of all due care in
  design, component selection, manufacture, and testing
  prior to sale, the pump and catheters may be damaged
  before, during, or after implantation by improper
  handling or filling; by drugs or uses not described in
  this technical manual; or by other intervening acts.
  Consequently, no representation or warranty is made
  that failure or cessation of function of the pump or
  catheters will not occur, or that the body will not
  react adversely to their implantation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A. 114.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   C.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In May 2003, physicians implanted the SynchroMed pump in Arnold
Walker, appellant Sherry Walker's late husband, for the purpose
of delivering medication to treat his chronic back pain. It is
undisputed that the pump functioned for approximately two
years.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On June 9, 2005, Arnold died from &mdash; according to his
death certificate &mdash; "[c]ombined hydromorphone,
hydrocodone, diazepam, and venlafaxine intoxication."<a HREF="#fn200" name="fnref_fn200">[fn2]</a> J.A.
29. During Arnold's autopsy, the SynchroMed pump was removed
and placed in a bag, where it continued to dispense
hydromorphone. Walker's expert, Dr. Harry Milman, later
analyzed the contents of the pump and the bag and concluded
that, based on the programmed hourly infusion rate at which the
medication was to be dispensed, 568 mg of hydromorphone were
unaccounted for. Milman opined that, prior to Arnold's death,
the SynchroMed pump had malfunctioned and overinfused the
unaccounted for hydromorphone into Arnold's body. He concluded
that this overinfusion by the SynchroMed pump was the cause of
death.<a HREF="#fn300" name="fnref_fn300">[fn3]</a>
<span CLASS="page_no" data-cite="670 f 3d 576" data-cite-type="PrimaryFederalReporter" data-cite-pageno="576" data-primary-citation="670 F.3d 569">[*576]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   D.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On May 18, 2007, Walker filed a diversity suit against
Medtronic in the United States District Court for the Southern
District of West Virginia. She alleged that the SynchroMed pump
had malfunctioned, resulting in Arnold's death from a lethal
overdose of medication. In her complaint, she asserted three
common law causes of action: negligence, strict liability, and
breach of warranty. She sought compensatory and punitive
damages, attorney's fees, costs, and pre-and post-judgment
interest.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On April 21, 2008, following the Supreme Court's decision in
<i>Riegel</i>, Medtronic moved for summary judgment, arguing
that Walker's claims were preempted. The district court denied
the motion without prejudice, finding that there was a dispute
of fact regarding whether the SynchroMed pump in question
complied with the terms of its premarket approval. The court
recognized, however, that Walker's original complaint did not
allege a claim that would survive <i>Riegel's</i> preemption
analysis. Consequently, it informed her that she could amend
the complaint to correct the deficiency.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Walker filed an amended complaint on October <span CLASS="page_no" data-cite="2012 bl 16026 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[**6]</span> 29, 2008. In her
amended complaint, she asserted the same three causes of action
but alleged for the first time that "the pump failed to comply
and operate in terms of its Pre-Market Approval." J.A. 40.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The parties then engaged in discovery to determine whether the
SynchroMed pump complied with the terms of is premarket
approval. During discovery, Medtronic produced reports
establishing that the particular SynchroMed pump implanted in
Arnold Walker had been tested prior to implantation and had
been determined to be in compliance with its premarket approval
terms.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On October 29, 2009, following discovery, Medtronic filed a
renewed motion for summary judgment. It argued that because
discovery had demonstrated that the SynchroMed pump was
designed, manufactured, and sold in accordance with its
pre-market approval, Walker's claims were preempted by the MDA
as interpreted by <i>Riegel.</i> Walker opposed the motion.
She did not dispute that the pump was designed, manufactured,
and sold in accordance with its premarket approval. Rather, she
asserted, as she does here, that her claims fell within the
exception for parallel claims articulated in <i>Riegel.</i>
Specifically, she argued that the pump had failed to adhere to
the plus or minus 15 percent specification included in the
pre-market approval materials and, that by failing to
administer medicine within these parameters, it had violated
the terms of its pre-market approval.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court granted Medtronic's renewed motion for
summary judgment. It reasoned that because Walker conceded that
the SynchroMed pump was designed, manufactured, and sold in
accordance with its premarket approval terms, her claims did
not parallel federal requirements. It also determined that,
because the plus or minus 15 percent flow accuracy rate
referenced in the SynchroMed pump's premarket approval
application was not a formal performance standard, failure to
adhere to the specification was not a violation of the
premarket approval. As such, the district court concluded that
all of Walker's common law tort claims were preempted by the
MDA.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   II.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal, Walker again asserts that her common law tort claims
are not preempted by the MDA because they fit within the narrow
exception for parallel
<span CLASS="page_no" data-cite="670 f 3d 577" data-cite-type="PrimaryFederalReporter" data-cite-pageno="577" data-primary-citation="670 F.3d 569">[*577]</span> 
claims the Supreme Court carved out in <i>Riegel.</i> We
review the district court's finding of preemption de novo.
<i>Equal Rights Ctr. v. Niles Bolton Assocs.</i>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X1D29QM003?jcsearch=602%20f%203d%20597&amp;summary=yes#jcite">602 F.3d 597</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X1D29QM003?jcsearch=602%20f%203d%20597&amp;summary=yes#jcite">600</a> (4th Cir. 2010). Here, we first discuss <i>Riegel</i>
and its effect on common law tort claims based on the failure
of FDA-approved medical devices. We then analyze Walker's
claims in light of <i>Riegel.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   A.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Riegel</i>, the Supreme Court considered whether a
plaintiffs common law claims based on the failure of a Class
III medical device were precluded by the MDA's express
preemption clause, which preempts state requirements "different
from, or in addition to" requirements applicable under federal
law. <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 321</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a> (quoting
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5Q2003?jcsearch=21%20U.S.C.%20%20360k(a)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 360k</a>(a)(1)). To answer this question, it engaged in a two-part
inquiry. <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 321-22</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. First, the Supreme
Court examined "whether the federal government ha[d]
established requirements <span CLASS="page_no" data-cite="2012 bl 16026 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[**7]</span> applicable to" the device in question.
<i></i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id. at 321</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. It specifically found that
"[p]remarket approval . . . imposes `requirements' under the
MDA." <i></i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id. at 322</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. This is because "the
FDA requires a device that has received pre-market approval to
be made with almost no deviations from the specifications in
its approval application, for the reason that the FDA has
determined that the approved form provides a reasonable
assurance of safety and effectiveness." <i></i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id. at 323</a>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. Therefore, because all Class III devices are
required to undergo the premarket approval process, federal
requirements exist with respect to all Class III devices.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, the <i>Riegel</i> Court considered whether the
plaintiffs common law claims imposed any requirements that were
"different from, or in addition to" these federal requirements
and "relate[d] to the safety or effectiveness of the device or
to any other matter included in a requirement of the device."
<i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id</a>.</i> (quoting <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5Q2003?jcsearch=21%20U.S.C.%20%20360k(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 360k</a>(a)). It first
recognized that common law liability necessarily implies that
the defendant had a legal duty and that "a liability award `can
be, indeed is designed to be, a potent method of governing
conduct and controlling policy.'" <i></i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id. at 324</a>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a> (quoting <i>Cipollone v. Liggett Group, Inc.</i>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X5CC63?jcsearch=505%20us%20504&amp;summary=yes#jcite">505 U.S. 504</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X5CC63?jcsearch=505%20us%20504&amp;summary=yes#jcite">521</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X5CC63?jcsearch=112%20supreme%20court%202608&amp;summary=yes#jcite">112 S.Ct. 2608</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X5CC63?jcsearch=120%20l%20ed%202d%20407&amp;summary=yes#jcite">120 L.Ed.2d 407</a> (1992)).
Common law duties, it went on to hold, therefore ordinarily
constitute state requirements. <i>Id.</i> It further observed
that "[s]tate tort law that requires [a device] to be safer,
but hence less effective, than the model the FDA has approved
disrupts the federal scheme no less than state regulatory law
to the same effect." <i></i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id. at 325</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In sum, the Supreme Court held that the terms of a Class III
device's premarket approval constitute federal requirements and
that a common law tort claim premised on different or
additional requirements is preempted by the MDA. Applying this
framework to Riegel's case, it concluded that her claims
against Medtronic were preempted.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court did recognize one situation in which a
plaintiffs common law claims would not be preempted under the
MDA: when "state duties . . . `parallel,' rather than add to,
federal requirements." <i></i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id. at 330</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>
(quoting <i>Medtronic, Inc. v. Lohr</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X5CCS2?jcsearch=518%20us%20470&amp;summary=yes#jcite">518 U.S. 470</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X5CCS2?jcsearch=518%20us%20470&amp;summary=yes#jcite">495</a>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X5CCS2?jcsearch=116%20supreme%20court%202240&amp;summary=yes#jcite">116 S.Ct. 2240</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X5CCS2?jcsearch=135%20l%20ed%202d%20700&amp;summary=yes#jcite">135 L.Ed.2d 700</a> (1996)). This situation occurs
when claims are "premised on a violation of FDA regulations."
<i>Id.</i> Because Riegel only raised the argument that her
claims paralleled federal requirements for the first time
before the Supreme Court, it declined to consider the claim.
<span CLASS="page_no" data-cite="670 f 3d 578" data-cite-type="PrimaryFederalReporter" data-cite-pageno="578" data-primary-citation="670 F.3d 569">[*578]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   B.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Here, Walker contends that her common law tort claims parallel
the federal requirements imposed by the SynchroMed pump's
premarket approval. She argues that the plus or minus 15
percent specification included in Medtronic's pre-market
approval materials became a part of the federal requirements
governing the device. Because the SynchroMed pump allegedly
infused an amount of medication outside of these parameters,
her argument follows, it violated the terms of the pre-market
approval. Walker has, however, made concessions that are fatal
to her claim.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Walker concedes that the SynchroMed pump was designed,
manufactured, and distributed in compliance with the terms of
the FDA's premarket <span CLASS="page_no" data-cite="2012 bl 16026 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[**8]</span> approval. She concedes that the plus or
minus 15 percent specification is <i>not</i> a formal
performance standard. And she acknowledges, as indeed she must,
that unless her claims parallel federal requirements as opposed
to imposing more stringent ones, they are preempted under the
MDA as interpreted by <i>Riegel.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   1.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We first note that this appeal is not about whether the plus or
minus 15 percent flow accuracy specification set forth in
Medtronic's premarket approval application constitutes a formal
performance standard (although, as we explain, it does not).
The issue before us is whether Walker's claims are preempted by
the MDA, as interpreted by the Supreme Court in
<i>Riegel</i>, which provides a rigorous, comprehensive, and
exclusive framework that precludes state law tort claims that
seek to impose different or higher standards upon federally
approved devices. Whether the plus or minus 15 percent
specification is a formal performance standard is pertinent
because only such a performance standard could create the type
of binding requirement that would make Walker's claims impose
requirements parallel to, as opposed to more restrictive than,
those imposed by the FDA. Thus, the status of the plus or minus
15 percent specification informs our resolution of the ultimate
question posed by this appeal: whether Walker's claims are
preempted by the MDA.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Simply because the majority recognizes that the plus or minus
15 percent specification does not create an ongoing
requirement, however, we do not state, or even suggest, that
the flow accuracy specification is a "mere aspirational
figure," as the dissent asserts. <i>Post</i> at 581. To the
contrary, it informs the medical community of the results the
device is likely to achieve under optimal circumstances. It
also imposes consequences when a SynchroMed pump does not meet
the specification. Specifically, Medtronic is required to
report any such malfunction to the FDA for consideration in its
ongoing evaluative process.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Instead, the majority simply concludes what is incontrovertible
under FDA regulations: the only mechanism for creating a
binding, ongoing performance requirement is the creation of a
performance standard. And Walker does not dispute that, here,
the plus or minus 15 percent specification is not a performance
standard. As such, it cannot bear the weight the dissent would
assign to it. Indeed, if we were to treat the flow rate as a
requirement, we would be imposing a heightened standard beyond
that of the FDA &mdash; which is impermissible under
<i>Riegel.</i> Moreover, as we have noted, such a holding
would upend the carefully calibrated construct Congress created
in the MDA, balancing the potential rewards of such devices
following the rigorous process of FDA approval against the cost
of preempting
<span CLASS="page_no" data-cite="670 f 3d 579" data-cite-type="PrimaryFederalReporter" data-cite-pageno="579" data-primary-citation="670 F.3d 569">[*579]</span> 
common law claims based on standards different than those
imposed by the FDA.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   2.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Riegel</i> held that, because of the congressional balance
reflected in the MDA, a plaintiffs state law cause of action
based on injuries caused by a Class III medical device could
only survive <span CLASS="page_no" data-cite="2012 bl 16026 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[**9]</span> if the alleged malfunction also violated a federal
requirement. Because the SynchroMed pump's premarket approval
application makes it clear that ongoing adherence to the plus
or minus 15 percent flow accuracy specification was not a
requirement, <a HREF="#fn400" name="fnref_fn400">[fn4]</a> Walker's claims based on the device's alleged
failure to adhere to the specification must fail.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As discussed above, the FDA may promulgate formal performance
standards to which a device must adhere as a condition of its
premarket approval. See <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PK003?jcsearch=21%20usc%20360d&amp;summary=yes#jcite">21 U.S.C. &sect; 360d</a>. The process of
creating a formal performance standard requires adherence to
specific procedures. <i>See </i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PK003?jcsearch=21%20U.S.C.%20%20360d&amp;summary=yes#jcite">id. at &sect; 360d(b)</a>. Because
the plus or minus 15 percent specification here was not a
formal performance standard, however, Walker cannot claim that
ongoing adherence to it was a requirement of the SynchroMed
pump's premarket approval.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  That ongoing adherence to the plus or minus 15 percent
specification was not a requirement of the device's premarket
approval is further demonstrated by the FDA approval letter and
the FDA-approved Technical Manual.<a HREF="#fn500" name="fnref_fn500">[fn5]</a> As noted above, the
approval letter referred to the plus or minus 15 percent
specification as a measure of "delivery accuracy"; it in no way
conditioned the device's approval on maintaining this metric.
J.A. 93. To the contrary, the letter contained a number of
specific "Conditions of Approval." J.A. 94. These detailed,
inter alia, restrictions on advertising and reporting
requirements. They did <i>not</i> include the plus or minus
15 percent specification &mdash; or any sort of performance
standard.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Further, the Technical Manual, also approved by the FDA,
contained a number of warnings making it clear that the plus or
minus 15 percent specification was subject to many variables.
It specifically stated that human error, <a HREF="#fn600" name="fnref_fn600">[fn6]</a> technical error,
or component
<span CLASS="page_no" data-cite="670 f 3d 580" data-cite-type="PrimaryFederalReporter" data-cite-pageno="580" data-primary-citation="670 F.3d 569">[*580]</span> 
failure could result in a change in flow accuracy. It also
clearly listed "over-infusion" and "drug overdose" as possible
consequences of device malfunction. J.A. 109. Finally, the
Technical Manual contained a general warning about the inherent
risks of implanting a device in the "extremely hostile
environment of the human body." J.A. 114.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In short, nothing in the SynchroMed pump's premarket approval
application &mdash; which was approved in its entirety by the
FDA &mdash; purported that the device would always dispense
medication within the range of the plus or minus 15 percent
flow accuracy. Instead, the plus or minus 15 percent
specification reflects the SynchroMed pump's output under
optimal conditions, but subject to numerous qualifiers that
disclose the possibility of infusion outside this range. To the
extent that Walker interprets the plus or minus 15 percent
specification as a guarantee of performance, she seeks to
impose a more demanding standard than that of the FDA, rather
than a parallel one.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On this record, we agree with the district court that "[a]n
alleged deviation from manufacturing performance specifications
for a device that has received pre-market approval is not the
same thing as noncompliance with the FDA or its regulations."
<i>Walker v. Medtronic, <span CLASS="page_no" data-cite="2012 bl 16026 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[**10]</span> Inc.</i>, <cite>No. 2:07-00317</cite>,
[<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X1EL55O003?jcsearch=2010%20BL%20278663&amp;summary=yes#jcite">2010 BL 278663</a>], 2010 WL 4822135, at *5 (S.D.W.Va. Nov. 24, 2010). To the contrary,
because Walker's argument would require that the SynchroMed
pump <i>never</i> deviate from its programmed flow rate by
more than plus or minus 15 percent, and the terms of the
device's premarket approval do not contemplate this result, she
is actually contending that the device should have been
designed differently. Stated another way, given that the
SynchroMed pump's premarket approval specifically included
language detailing the possibility of deviation from the plus
or minus 15 percent specification, it necessarily follows that
any design that eliminated the possibility of such variation
would be "different from, or in addition to" the design
approved by the FDA. <i>See</i> <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5Q2003?jcsearch=21%20U.S.C.%20%20360k(a)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 360k</a>(a)(1).
As the <i>Riegel</i> court noted, however, "the FDA requires
a device that has received premarket approval to be made with
almost no deviations from the specifications in its approval
application, for the reason that the FDA has determined that
the approved form provides a reasonable assurance of safety and
effectiveness." <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 323</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. A common law
tort claim that presupposes a Class III device should have been
designed in a manner other than that contemplated by its
premarket approval is therefore expressly preempted by the MDA
as interpreted by <i>Riegel. </i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id. at 324-25</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We note that, in granting premarket approval, the FDA did
precisely what the dissent would have it do: it evaluated,
through a rigorous process, the safety and reliability of the
device at issue. It also recognized, however, that the device's
safety and reliability cannot be guaranteed indefinitely in the
"extremely hostile environment of the human body," where myriad
other factors external to the device are brought to bear
(although the device at issue here did function in such an
environment, without dispute, for approximately two years).
J.A. 114. It is Walker's attempt to transform a <i>design</i>
<i>specification</i>, which the FDA recognizes the device will
not always function in accordance with, into an actionable
guarantee, that seeks to impose an additional requirement as
precluded under <i>Riegel.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The consensus of the federal courts post-<i>Riegel</i>
supports our conclusion. Specifically, numerous district courts
have held that common law tort claims based on
<span CLASS="page_no" data-cite="670 f 3d 581" data-cite-type="PrimaryFederalReporter" data-cite-pageno="581" data-primary-citation="670 F.3d 569">[*581]</span> 
the failure of devices that were designed, manufactured,
and sold in accordance with the terms of their premarket
approval were preempted under <i>Riegel. See, e.g., Rankin v.</i>
<i>Boston Scientific Corp.</i>, No. <cite>09-177-KSF</cite>, [<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XKG0RON?jcsearch=2010%20BL%20318634&amp;summary=yes#jcite">2010 BL 318634</a>], 2010 WL 672135,
at *4 (E.D.Ky. Feb. 19, 2010) ("Boston Scientific received
premarket approval for the Maverick Balloon at issue in this
case. The fact that the Maverick Balloon allegedly failed
during normal use does not override the clear language of
&sect; 360(a) or the Supreme Court's ruling in <i>Riegel</i> that
the plaintiffs' claims are preempted by federal law.");
<i>Banner v. Cyberonics, Inc.</i>, <cite>No. 08-0741</cite>,
[<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X1CFVSM003?jcsearch=2010%20BL%2023705&amp;summary=yes#jcite">2010 BL 23705</a>], 2010 WL 455286, at *4 (D.N.J. Feb. 4, 2010) ("[I]f the FDA approves a
manufacturing process and the defendant-manufacturer conforms
with it, a device thereby produced that nevertheless does not
function as intended does not give rise to liability.");
<i>Williams v. Cyberonics, <span CLASS="page_no" data-cite="2012 bl 16026 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[**11]</span> Inc.</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X1BMTAG003?jcsearch=654%20f%20supp%202d%20301&amp;summary=yes#jcite">654 F.Supp.2d 301</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X1BMTAG003?jcsearch=654%20f%20supp%202d%20301&amp;summary=yes#jcite">306</a>
(E.D.Pa. 2009), <i>aff'd</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X1DP3SS003?jcsearch=388%20f%20appx%20169&amp;summary=yes#jcite">388 Fed.Appx. 169</a> (3d Cir. 2010)
(unpublished) ("To avoid federal preemption, a plaintiff must
make some showing that the medical device was not manufactured
in accordance with FDA standards."); <i>Clark v. Medtronic,</i>
<i>Inc.</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X19EDOI003?jcsearch=572%20f%20supp%202d%201090&amp;summary=yes#jcite">572 F.Supp.2d 1090</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X19EDOI003?jcsearch=572%20f%20supp%202d%201090&amp;summary=yes#jcite">1095</a> (D.Minn. 2008) ("Because
plaintiffs claims are not based on a breach of the MDA as
enforced by the FDA, the claims are not grounded in state laws
that `parallel' federal requirements. Thus, plaintiffs claims
are preempted."). Neither Walker nor the dissent point to any
case law, nor have we found any, in which a court has reached a
contrary conclusion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because the SynchroMed pump was undisputedly designed,
manufactured, and distributed in compliance with its FDA
premarket approval, and Walker's common law claims exceed or
differ from, rather than parallel, federal requirements, we
hold that each of her specific claims for negligence, strict
liability, and breach of warranty is preempted.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                  III.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For the foregoing reasons, the judgment of the district court
is
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>AFFIRMED.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> The FDA may also "recognize . . . an appropriate standard
established by a nationally or internationally recognized
standard development organization" by publishing such a
standard in the Federal Register.
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PK003?jcsearch=21%20U.S.C.%20%20360d(c)(1)(A)&amp;summary=yes#jcite">21 U.S.C. &sect; 360d</a>(c)(1)(A).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> At the time of Arnold's death, he was being treated
orally with hydrocodone, diazepam, and venlafaxine. The only
medication he was receiving via the SynchroMed Infusion System
was hydromorphone.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> Medtronic vigorously contests Walker's theory that an
overinfusion by the SynchroMed pump caused her husband's death.
It recognizes, however, that this factual dispute is irrelevant
to the question of whether Walker's claims are preempted by the
MDA. Because when reviewing a grant of summary judgment, we
"view[] the facts in the light most favorable to the nonmoving
party," we recount the facts here in the light most favorable
to Walker. <i>See Nat'l City Bank of In. v. Turnbaugh</i>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X15GS80003?jcsearch=463%20f%203d%20325&amp;summary=yes#jcite">463 F.3d 325</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X15GS80003?jcsearch=463%20f%203d%20325&amp;summary=yes#jcite">329</a> (4th Cir. 2006).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> With respect for the dissent's suggestion to the
contrary, we note that the opinion of one Medtronic employee,
expressed during a deposition, regarding whether an
overinfusion of the SynchroMed pump would constitute a
violation of the device's premarket approval has no bearing on
the question of whether the <i>FDA</i> conditioned its
premarket approval of the device upon ongoing adherence to the
plus or minus 15 percent flow rate.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> We do not necessarily disagree with the dissent's
assertion that "the FDA's [premarket] approval and the
Conditions of Approval, taken together, . . . establish[] the
specific federal requirements for" a Class III device. <i>Kemp</i>
<i>v. Medtronic, Inc.</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X3FMTV?jcsearch=231%20f%203d%20216&amp;summary=yes#jcite">231 F.3d 216</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X3FMTV?jcsearch=231%20f%203d%20216&amp;summary=yes#jcite">228</a> (6th Cir. 2000). That
a specification is included in a device's premarket approval
application, however, does not indicate that the specification
imposes a binding requirement for the life of the device
&mdash; at least not without clear indication by the FDA
through promulgation of a formal performance standard. Here, it
is undisputed that the SynchroMed pump at issue was designed,
manufactured, and sold in compliance with the terms of its
premarket approval &mdash; including the plus or minus 15
percent specification. As we explain, without an express
statement in the FDA's approval materials that the SynchroMed
pump was subject to an ongoing requirement that it never
deviate from the plus or minus 15 percent specification, any
attempt to impose one through civil tort liability would impose
additional requirements in violation of the MDA as interpreted
by <i>Riegel.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> It should be noted that nothing in our preemption
discussion precludes a state tort claim against a physician who
improperly implants the pump or otherwise negligently causes it
to malfunction. Walker has not, however, made any such
allegation here.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  WYNN, Circuit Judge, dissenting:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This case boils down to a choice of whether the Federal
Drug Administration's ("FDA") specification that a potentially
deadly medical device, an internally implanted pump,
"maintain[] the delivery accuracy of &plusmn; 15%" (J.A. 93) is
a requirement, or whether it is a mere aspirational figure.
Because I believe that the accuracy rate specification is
indeed a requirement, and because the medical device's failure
to meet that requirement underlies Plaintiff Sherry Walker's
state law tort claims, I would hold that her claims are not
preempted under <i>Riegel v. Medtronic, Inc.</i>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. 312</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=169%20l%20ed%202d%20892&amp;summary=yes#jcite">169 L.Ed.2d 892</a> (2008). I therefore
respectfully dissent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Riegel</i>, the Supreme Court expressly stated that
state tort suits are preempted only to the extent that they
impose requirements "different from, or in addition to" the
requirements imposed by federal law. <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 321</a>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. The Supreme Court affirmed a Second Circuit opinion that
emphasized at the outset that
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  our preemption analysis is quite limited in scope,
  affecting the small universe of cases resting on
  claims alleging liability despite a
  [premarket]-approved device's adherence to the
  standards upon which it secured FDA premarket
  approval. We take care to explain that we do not hold
  that all state tort claims as to [premarket]-approved
  devices are preempted. Thus, <i>tort claims that are</i>
  <i>based on a manufacturer's departure from the standards</i>
  <i>set forth in the device's approved [Pre-Market</i>
  <i>Approval] application</i> &mdash; such
<span CLASS="page_no" data-cite="670 f 3d 582" data-cite-type="PrimaryFederalReporter" data-cite-pageno="582" data-primary-citation="670 F.3d 569">[*582]</span> 
  as the Riegels' negligent manufacturing claim &mdash;
  <i>are not preempted.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Riegel v. Medtronic, Inc.</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X1526LU003?jcsearch=451%20f%203d%20104&amp;summary=yes#jcite">451 F.3d 104</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X1526LU003?jcsearch=451%20f%203d%20104&amp;summary=yes#jcite">106</a> (2d
Cir. 2006) (emphasis added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court established a two-step analysis for
determining if state-law claims are preempted. First, a court
must determine whether "the Federal Government has established
requirements applicable to" the particular medical device.
<i>Riegel</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 321</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. Claims
involving a Class III medical device with Pre-Market Approval
automatically clear step one of the analysis because the
Pre-Market Approval process establishes specific requirements
applicable to the particular device. <i></i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id. at 322-23</a>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. In the second step, a court must determine
whether the state <span CLASS="page_no" data-cite="2012 bl 16026 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[**12]</span> law claims are based on requirements
"different from or in addition to" the federal requirements
relating to safety and effectiveness. <i></i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id. at 323</a>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a> (quotation marks omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In my view, Walker's suit clears both of these hurdles. The
Medtronic SynchroMed EL Infusion Pump ("Pump") at issue in this
case is undisputedly a Class III device with specific
requirements. The first <i>Riegel</i> step is therefore met.
Further, the Pre-Market Approval established a plus or minus 15
percent delivery accuracy requirement for the
internally-implanted Medtronic SynchroMed EL Infusion Pump
("Pump"). Walker's suit is based on the Pump's failure to meet
that requirement. Indeed, she proffered evidence, which we must
take as true for summary judgment purposes, that her husband,
Arnold Walker, died because the Pump delivered an extreme
overdose of 258 percent of his prescribed medicine dosage.
Walker's suit therefore does not impose additional or different
requirements but rather parallels the pre-existing federal
requirements for the Pump. I therefore do not believe that her
suit is preempted under <i>Riegel.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority casts the Federal Drug Administration's ("FDA")
requirement that the Pump "maintain[] the delivery accuracy of
&plusmn; 15%" (J.A. 93) as a mere aspirational figure, i.e.,
what "the device is likely to achieve under optimal
circumstances." <i>Ante</i> at 578. I cannot agree. And,
apparently, neither would the FDA. In an amicus brief filed in
<i>Horn v. Thoratec Corp.</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEQ9JN?jcsearch=376%20f%203d%20163&amp;summary=yes#jcite">376 F.3d 163</a> (2004), in which
the Third Circuit addressed whether state claims were
preempted, the FDA stated that "the agency's approval of this
[Class III] device through <i>the PMA process does impose</i>
<i>specific requirements for</i> its design, manufacturing,
<i>performance</i>, labeling, and use." Brief for the United
States as Amicus Curiae at 15, <i>Horn v. Thoratec Corp.</i>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEQ9JN?jcsearch=376%20f%203d%20163&amp;summary=yes#jcite">376 F.3d 163</a> (3d Cir. 2004) (<cite>No. 02-4597</cite>), [<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEQ9JN?jcsearch=376%20F.3d%20163&amp;summary=yes#jcite">376 F.3D 163</a>], 2004 WL 1143720, at
*15 (emphasis added). Further, "in reviewing a PMA, FDA
considers in great depth and detail the <i>performance</i>
and design <i>specifications</i>, methods of manufacture,
labeling, and indications for use of a proposed medical
device." Amicus Br. at 16. Nowhere in its 31-page brief did the
FDA even <i>mention</i> the words "performance standard."
Nevertheless, the FDA repeatedly made clear that it can and
does exact performance specifications and requirements in the
ordinary course of the Pre-Market Approval process &mdash;
which is precisely what we have in this case.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA underscored that "<i>although FDA does not itself</i>
<i>design any medical devices, through the PMA approval process it</i>
<i>certainly establishes `specific requirements' applicable to a</i>
<i>`particular device' because the specifications for that</i>
<i>device's</i> design, <i>performance</i>, manufacture,
labeling, and use <i>are approved by the agency based on what</i>
<i>the applicant submits.</i>
<span CLASS="page_no" data-cite="670 f 3d 583" data-cite-type="PrimaryFederalReporter" data-cite-pageno="583" data-primary-citation="670 F.3d 569">[*583]</span> 
<i>See Kemp v. Medtronic, Inc.</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X3FMTV?jcsearch=231%20f%203d%20216&amp;summary=yes#jcite">231 F.3d at 216</a>."
<i></i><cite>Id. at 16</cite> (emphasis added). And, notably, "<i>FDA</i>
<i>does not, and has never, used notice-and-comment</i>
<i>regulations</i>" &mdash; and formal performance standards are
just such regulations, as the majority recognizes &mdash;
"<i>to approve individual products or to establish</i>
<i>product-specific requirements for</i> manufacture,
<i>performance</i>, labeling, and use. Rather, a <span CLASS="page_no" data-cite="2012 bl 16026 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[**13]</span> PMA order is
better conceptualized as an individual adjudication that
imposes `specific requirements' on the device." <i></i><cite>Id.
at 23-24</cite> (emphasis added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Accordingly, the accuracy rate at issue here is a requirement
for the Pump per the Pre-Market Approval. The accuracy rate of
"delivery accuracy of &plusmn; 15%" is included twice in the
PMA approval, which itself was based on information that
Medtronic provided and that included the figure. J.A. 93-94.
Medtronic itself argued in a previous appeal before the Sixth
Circuit that "the FDA's [Pre-Market] [A]pproval and the
Conditions of Approval, taken together, . . . establish[] the
specific federal requirements for the" device at issue.
<i>Kemp v. Medtronic</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X3FMTV?jcsearch=231%20f%203d%20216&amp;summary=yes#jcite">231 F.3d 216</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X3FMTV?jcsearch=231%20f%203d%20216&amp;summary=yes#jcite">228</a> (6th Cir. 2000)
(quotation marks omitted). The Sixth Circuit agreed with
Medtronic's position &mdash; and so do I. <i>See <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X3FMTV?jcsearch=231%20F.3d%20216&amp;summary=yes#jcite">id</a>.; see also</i>
<i>Horn</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEQ9JN?jcsearch=376%20f%203d%20163&amp;summary=yes#jcite">376 F.3d at 171</a> ("The FDA, when PMA approval is
granted, imposes federal requirements based on the highly
detailed and prescriptive nature of the PMA process and the
approval order that results from it."). Indeed, even in this
litigation, Medtronic conceded that an overinfusion of
medication above 15 percent would violate the Pump's Pre-Market
Approval. Medtronic's corporate representative for purposes of
this case, Patrick L. Johnson, Regulatory Affairs Director for
the Medtronic Neurological Business, testified in his
deposition as follows:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Q: Okay. Let me rephrase it then. Assuming there are
  no procedural errors, the physician hasn't done
  anything wrong and Mr. Walker's pump has been used
  within the environmental conditions that are spelled
  out in the technical manual and the pump because of a
  system complication, a system error overinfuses Mr.
  Walker by more than 15 percent, that would be a
  violation of the PMA approval for this pump, would you
  agree with that?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A: That would be a reasonable statement, yes.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
S.J.A.<a HREF="#fn101" name="fnref_fn101">[fn1]</a> 248 (objection to form omitted). That is precisely
what Walker is claiming.<a HREF="#fn201" name="fnref_fn201">[fn2]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority notes that "neither the FDA's initial grant of
premarket approval nor its later approvals of supplemental
applications [for the Pump] were subject to any requirement
that [the Pump] comply with a formal performance standard
pursuant to <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XEI5PK003?jcsearch=21%20U.S.C.%20%20360d&amp;summary=yes#jcite">&sect; 360d</a>." <i>Ante</i> at 574. The majority
then goes on, however, to assert, without citation to any
support, that "only such a performance standard could create
the type of binding requirement that would make Walker's claims
impose requirements parallel to, as opposed to more restrictive
than, those imposed by the FDA." <i>Ante</i> at 578. I cannot
agree that the absence of a formal performance standard for
this Class III device frees the manufacturer from
accountability for ensuring that
<span CLASS="page_no" data-cite="670 f 3d 584" data-cite-type="PrimaryFederalReporter" data-cite-pageno="584" data-primary-citation="670 F.3d 569">[*584]</span> 
its device performs as approved, including with regard to
the approved accuracy rate.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is instructive to consider what a formal performance
standard is. "Medical devices are developed individually, but
classes of products with similar features can sometimes benefit
from a uniform standard of safety and effectiveness. These are
the Class II devices." James T. O'Reilly, 1 <i>Food &amp; Drug</i>
<i>Admin.</i> <cite>&sect; 18:18</cite> (3d ed. 2011). Performance standards
are a form of special control that <span CLASS="page_no" data-cite="2012 bl 16026 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[**14]</span> may be instituted when
"[t]he FDA . . . make[s] a finding that a performance standard
is necessary to provide reasonable assurance of the device's
safety and efficacy." <i><cite>Id</cite>.</i> (quotation marks omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Notably, however, to obtain Pre-Market Approval, a Class III
device manufacturer must always "provide[] reasonable assurance
that the product is safe and effective under the conditions of
use for which it is labeled. . . ." <i><cite>Id</cite>.</i> at
<cite>&sect; 18:50</cite>. This is echoed in <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XMJ9M6003?jcsearch=21%20cfr%20860%207&amp;summary=yes#jcite">21 C.F.R. &sect; 860.7</a>, the regulation
dedicated to the "[d]etermination of safety and
effectiveness[,]" which equates the establishment of
performance standards for Class II devices with the Pre-Market
Approval of Class III devices. The regulation states:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>In determining the safety and effectiveness of a</i>
  <i>device for purposes</i> of classification,
  establishment of performance standards for class II
  devices, and pre-<i>market approval of class III</i>
  <i>devices, the Commissioner and the classification</i>
  <i>panels will consider the following, among other</i>
  <i>relevant factors</i>:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (1) The persons for whose use the device is
  represented or intended;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (2) The conditions of use for the device, including
  conditions of use prescribed, recommended, or
  suggested in the labeling or advertising of the
  device, and other intended conditions of use;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (3) The probable benefit to health from the use of the
  device weighed against any probable injury or illness
  from such use; and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (4) <i>The reliability of the device.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XMJ9M6003?jcsearch=21%20C.F.R.%20%20860.7(b)&amp;summary=yes#jcite">21 C.F.R. &sect; 860.7</a>(b) (emphasis added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Stated differently, as part of <i>every</i> Pre-Market
Approval for a Class III device (in contrast to a Class II
device, where these concerns come into play specifically in
establishing formal performance standards), the FDA must
evaluate "safety and effectiveness" by considering, among other
things, "[t]he reliability of the device" and the device's
potential injury versus potential benefit. <i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XMJ9M6003?jcsearch=21%20C.F.R.%20%20860.7(b)&amp;summary=yes#jcite">Id</a>.</i> Given
that even the FDA equates a safety and effectiveness
determination, including consideration of device reliability,
in Pre-Market Approvals for Class III devices with performance
standards for Class II devices, <a HREF="#fn301" name="fnref_fn301">[fn3]</a> I cannot agree with the
majority that "[b]ecause the plus or minus 15 percent
specification here was not a formal performance standard, . . .
Walker cannot claim that ongoing adherence to it was a
requirement of the [Pump's] premarket approval." <i>Ante</i>
at 579. Indeed, it seems illogical that the FDA would place
more exacting performance requirements on Class II devices such
as "surgical drapes" (<i>Riegel</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 316</a>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>) than on Class III devices such as "replacement heart
valves, implanted cerebella stimulators, and pace-maker pulse
generators," for which "a less stringent classification would
provide [no] reasonable assurance of safety and
effectiveness. . . ." <i></i><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id.: at 317</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18HPKU003?jcsearch=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>.
<span CLASS="page_no" data-cite="670 f 3d 585" data-cite-type="PrimaryFederalReporter" data-cite-pageno="585" data-primary-citation="670 F.3d 569">[*585]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Nor do I believe that Medtronic's inclusion of various warnings
in its Pre-Market Approval materials neuters the "maintaining
the delivery accuracy of &plusmn; 15%" requirement. Those
warnings address, e.g., potential component failure, conditions
under which the device might malfunction (such as at high
altitudes), and human error. Those general warnings do not
change the fact that the specific plus or minus <span CLASS="page_no" data-cite="2012 bl 16026 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[**15]</span> 15 percent
accuracy rate requirement is twice stated in the FDA's two-page
Pre-Market Approval letter, which, per Medtronic, establishes a
device's requirements. <i>See Kemp</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X3FMTV?jcsearch=231%20f%203d%20216&amp;summary=yes#jcite">231 F.3d at 228</a>.
Further, Medtronic has not alleged that any number of the
things addressed by the warnings are in play here (e.g.,
Medtronic does not contend that Arnold Walker went hiking in
the Himalayas).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To be sure, it cannot be said that, under my analysis, device
manufacturers must achieve perfection. Indeed, "the delivery
accuracy of &plusmn; 15%" itself recognizes that manufacturers
may be given some margin for error. The FDA accepted that
margin, based on Medtronic's Pre-Market Approval application,
to be plus or minus 15 percent. Perhaps potential liability for
incidents that occur outside of that 30 percent margin for
error is simply a cost of doing business. The ramifications of
holding anything else are indeed serious. If manufacturers are
not held accountable for having their devices perform as
approved by the FDA, they will have little incentive to ensure
that potentially deadly devices function properly. For example,
if Walker's factual contentions are true (and we must presume
that they are in reviewing summary judgment against her
(<i>Nat'l City Bank of In. v. Turnbaugh</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X15GS80003?jcsearch=463%20f%203d%20325&amp;summary=yes#jcite">463 F.3d 325</a>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X15GS80003?jcsearch=463%20f%203d%20325&amp;summary=yes#jcite">329</a> (4th Cir. 2006))), the Pump, which was approved with a
dosage accuracy rate of plus or minus 15 percent, instead
infused her husband with 258 percent of the appropriate
medication dosage, and this extreme overdose killed him. I fail
to see why &mdash; in the absence of clear congressional
instruction to the contrary &mdash; the Walkers alone should
bear the burden of this malfunction.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  My view is bolstered by the general presumption against
preemption of state law claims. As this Court articulated in a
2008 opinion, "we begin our consideration with the basic
premise that `Congress did not intend to displace state law.'
<i>Maryland v. Louisiana</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X5CA4A?jcsearch=451%20us%20725&amp;summary=yes#jcite">451 U.S. 725</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X5CA4A?jcsearch=451%20us%20725&amp;summary=yes#jcite">746</a>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X5CA4A?jcsearch=101%20supreme%20court%202114&amp;summary=yes#jcite">101 S.Ct. 2114</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X5CA4A?jcsearch=68%20l%20ed%202d%20576&amp;summary=yes#jcite">68 L.Ed.2d 576</a> (1981). . . . The presumption against
preemption has particular force in the areas of public health
and safety that have traditionally been regulated by the
states. <i>See Pinney v. Nokia, Inc.</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XNSUPGII8BG0?jcsearch=402%20f%203d%20430&amp;summary=yes#jcite">402 F.3d 430</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XNSUPGII8BG0?jcsearch=402%20f%203d%20430&amp;summary=yes#jcite">457</a>
(4th Cir.), <i>cert. denied</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X13GCO6003?jcsearch=546%20us%20998&amp;summary=yes#jcite">546 U.S. 998</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X13GCO6003?jcsearch=126%20supreme%20court%20551&amp;summary=yes#jcite">126 S.Ct. 551</a>,
<a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X13GCO6003?jcsearch=126%20supreme%20court%20551&amp;summary=yes#jcite">552</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X13GCO6003?jcsearch=163%20l%20ed%202d%20499&amp;summary=yes#jcite">163 L.Ed.2d 499</a> (2005)." <i>City of Falls Church v.</i>
<i>Fairfax Cnty. Water Auth.</i>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18NNEO003?jcsearch=272%20f%20appx%20252&amp;summary=yes#jcite">272 Fed.Appx. 252</a>, <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X18NNEO003?jcsearch=272%20f%20appx%20252&amp;summary=yes#jcite">256</a> (4th
Cir. 2008) (unpublished). Particularly when viewed through this
lens, I fail to see how Walker's claims are preempted.<a HREF="#fn401" name="fnref_fn401">[fn4]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Of course, whether or not Walker can prevail on her claims
remains a very open question. But at stake today is not whether
Walker should win or Medtronic should be held liable. The
question before us is simply whether Walker may pursue her
<span CLASS="page_no" data-cite="670 f 3d 586" data-cite-type="PrimaryFederalReporter" data-cite-pageno="586" data-primary-citation="670 F.3d 569">[*586]</span> 
state law tort claims in light of the FDA's regulation of
the Pump. I believe that she should be able to do so.
Accordingly, I respectfully dissent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn101" name="fn101">[fn1]</a></span> Certain case materials containing confidential medical
information relating to Arnold Walker were filed under seal.
While this deposition excerpt is found in the sealed joint
appendix, it does not pertain to confidential medical
information.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn201" name="fn201">[fn2]</a></span> I also note that even Medtronic's appellate counsel
conceded at oral argument that delivery of more than plus or
minus 15 percent of the appropriate dosage of medicine would
constitute a Pump "malfunction."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn301" name="fn301">[fn3]</a></span> I of course recognize that the FDA "<i>may</i>" (and
therefore necessarily need not) establish a performance
standard for Class III devices "as a condition to premarket
approval. . . ." <a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/XMJ9N4003?jcsearch=21%20C.F.R.%20%20861.1(b)&amp;summary=yes#jcite">21 C.F.R. &sect; 861.1</a>(b) (emphasis
added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn401" name="fn401">[fn4]</a></span> The majority appears to turn the presumption
<i>against</i> preemption on its head when it asserts "That a
specification is included in a device's premarket approval
application, however, does not indicate that the specification
imposes a binding requirement for the life of the device
&mdash; at least not without clear indication by the FDA
through promulgation of a formal performance standard."
<i>Ante</i> at 579 n. 5. Under the majority's analysis, then,
in clear contradiction to precedent, we assume preemption,
i.e., additional requirements via state tort suits, absent
clear indication to the contrary. With this, I cannot
agree.
</p></div>
<!--BBLS DD 1684864040963-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1H14RI003/history">Direct History (5)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1H14RI003/analysis">Case Analysis (8)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1H14RI003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
8
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Medical Devices</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/2ea6e549928ae1522970500c9cdba52f/document/X1Q6LF7G6M82">10-02219 (4th Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Products Liability</div><div class='facetItemLabel'>Torts</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/2ea6e549928ae1522970500c9cdba52f/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "2ea6e549928ae1522970500c9cdba52f";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYefe9bb&previousPageId=&previousActivityInstanceId=ENTITY94e570&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:34:31-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1H14RI003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY94e570&previousPageId=&previousActivityInstanceId=ENTITYe1c392&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:34:22-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1H14RI003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1H14RI003";
$('#page_loader').show().spin();
JUDGE_IDS=["16305167","3406768","3685752"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
